Chester County Hospital

Summary

Chester County Hospital is a medical facility located in West Chester, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Fallopian Tube Cancer and other specialties. Chester County Hospital is involved with conducting 95 clinical trials across 155 conditions. There are 3 research doctors associated with this hospital, such as William E. Luginbuhl, Maureen Hewitt, MD, and Andre A. Konski.

Top PIs

Clinical Trials running at Chester County Hospital

Ovarian Cancer

Breast Cancer

Uterine Cancer

Prostate Cancer

Depression

Endometrial Adenocarcinoma

Prostate Adenocarcinoma

Colon Cancer

Neonatal Sepsis

Peritoneal Adenocarcinoma

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Recruiting

1 award

N/A